OBJECTIVE: To determine whether, in children, plasma glial fibrillary acidic protein is associated with brain injury during extracorporeal membrane oxygenation and with mortality. DESIGN: Prospective, observational study. SETTING: Pediatric intensive care unit in an urban tertiary care academic center. PATIENTS: Neonatal and pediatric patients on extracorporeal membrane oxygenation (n = 22). INTERVENTIONS: Serial blood sampling for glial fibrillary acidic protein measurements. MEASUREMENTS AND MAIN RESULTS: Prospective patients age 1 day to 18 yrs who required extracorporeal membrane oxygenation from April 2008 to August 2009 were studied. Glial fibrillary acidic protein was measured using an electrochemiluminescent immunoassay developed at Johns Hopkins. Control samples were collected from 99 healthy children (0.5-16 yrs) and 59 neonatal intensive care unit infants without neurologic injury. In controls, the median glial fibrillary acidic protein concentration was 0.055 ng/mL (interquartile range, 0-0.092 ng/mL) and the 95th percentile of glial fibrillary acidic protein was 0.436 ng/mL. In patients on extracorporeal membrane oxygenation, plasma glial fibrillary acidic protein was measured at 6, 12, and every 24 hrs after cannulation. We enrolled 22 children who underwent extracorporeal membrane oxygenation. Median age was 7 days (interquartile range, 2 days to 9 yrs), and primary extracorporeal membrane oxygenation indication was: cardiac failure, six of 22 (27.3%); respiratory failure, 12 of 22 (54.5%); extracorporeal cardiopulmonary resuscitation, three of 22 (13.6%); and sepsis, one of 22 (4.6%). Seven of 22 (32%) patients developed acute neurologic injury (intracranial hemorrhage, brain death, or cerebral edema diagnosed by imaging). Fifteen of 22 (68%) survived to hospital discharge. In the extracorporeal membrane oxygenation group, peak glial fibrillary acidic protein levels were higher in children with brain injury than those without (median, 5.9 vs. 0.09 ng/mL, p = .04) and in nonsurvivors compared with survivors to discharge (median, 5.9 vs. 0.09 ng/mL, p = .04). The odds ratio for brain injury for glial fibrillary acidic protein >0.436 ng/mL vs. normal was 11.5 (95% confidence interval, 1.3-98.3) and the odds ratio for mortality was 13.6 (95% confidence interval, 1.7-108.5). CONCLUSIONS: High glial fibrillary acidic protein during extracorporeal membrane oxygenation is significantly associated with acute brain injury and death. Brain injury biomarkers may aid in outcome prediction and neurologic monitoring of patients on extracorporeal membrane oxygenation to improve outcomes and benchmark new therapies.
OBJECTIVE: To determine whether, in children, plasma glial fibrillary acidic protein is associated with brain injury during extracorporeal membrane oxygenation and with mortality. DESIGN: Prospective, observational study. SETTING: Pediatric intensive care unit in an urban tertiary care academic center. PATIENTS: Neonatal and pediatric patients on extracorporeal membrane oxygenation (n = 22). INTERVENTIONS: Serial blood sampling for glial fibrillary acidic protein measurements. MEASUREMENTS AND MAIN RESULTS: Prospective patients age 1 day to 18 yrs who required extracorporeal membrane oxygenation from April 2008 to August 2009 were studied. Glial fibrillary acidic protein was measured using an electrochemiluminescent immunoassay developed at Johns Hopkins. Control samples were collected from 99 healthy children (0.5-16 yrs) and 59 neonatal intensive care unit infants without neurologic injury. In controls, the median glial fibrillary acidic protein concentration was 0.055 ng/mL (interquartile range, 0-0.092 ng/mL) and the 95th percentile of glial fibrillary acidic protein was 0.436 ng/mL. In patients on extracorporeal membrane oxygenation, plasma glial fibrillary acidic protein was measured at 6, 12, and every 24 hrs after cannulation. We enrolled 22 children who underwent extracorporeal membrane oxygenation. Median age was 7 days (interquartile range, 2 days to 9 yrs), and primary extracorporeal membrane oxygenation indication was: cardiac failure, six of 22 (27.3%); respiratory failure, 12 of 22 (54.5%); extracorporeal cardiopulmonary resuscitation, three of 22 (13.6%); and sepsis, one of 22 (4.6%). Seven of 22 (32%) patients developed acute neurologic injury (intracranial hemorrhage, brain death, or cerebral edema diagnosed by imaging). Fifteen of 22 (68%) survived to hospital discharge. In the extracorporeal membrane oxygenation group, peak glial fibrillary acidic protein levels were higher in children with brain injury than those without (median, 5.9 vs. 0.09 ng/mL, p = .04) and in nonsurvivors compared with survivors to discharge (median, 5.9 vs. 0.09 ng/mL, p = .04). The odds ratio for brain injury for glial fibrillary acidic protein >0.436 ng/mL vs. normal was 11.5 (95% confidence interval, 1.3-98.3) and the odds ratio for mortality was 13.6 (95% confidence interval, 1.7-108.5). CONCLUSIONS: High glial fibrillary acidic protein during extracorporeal membrane oxygenation is significantly associated with acute brain injury and death. Brain injury biomarkers may aid in outcome prediction and neurologic monitoring of patients on extracorporeal membrane oxygenation to improve outcomes and benchmark new therapies.
Authors: C Foerch; I Curdt; B Yan; F Dvorak; M Hermans; J Berkefeld; A Raabe; T Neumann-Haefelin; H Steinmetz; M Sitzer Journal: J Neurol Neurosurg Psychiatry Date: 2005-09-20 Impact factor: 10.154
Authors: Linda E Pelinka; Alfred Kroepfl; Martin Leixnering; Walter Buchinger; Andreas Raabe; Heinz Redl Journal: J Neurotrauma Date: 2004-11 Impact factor: 5.269
Authors: Bahaaldin Alsoufi; Osman O Al-Radi; Rakan I Nazer; Colleen Gruenwald; Celeste Foreman; William G Williams; John G Coles; Christopher A Caldarone; Desmond G Bohn; Glen S Van Arsdell Journal: J Thorac Cardiovasc Surg Date: 2007-10 Impact factor: 5.209
Authors: Manon N Hanekamp; Petra Mazer; Monique H M van der Cammen-van Zijp; Boudien J M van Kessel-Feddema; Maria W G Nijhuis-van der Sanden; Simone Knuijt; Jessica L A Zegers-Verstraeten; Saskia J Gischler; Dick Tibboel; Louis A A Kollée Journal: Crit Care Date: 2006 Impact factor: 9.097
Authors: Maria Andrikopoulou; Ahmad Almalki; Azadeh Farzin; Christina N Cordeiro; Michael V Johnston; Irina Burd Journal: Int J Dev Neurosci Date: 2014-04-24 Impact factor: 2.457
Authors: Chengjian Tu; Kay D Beharry; Xiaomeng Shen; Jun Li; Lianshui Wang; Jacob V Aranda; Jun Qu Journal: J Proteome Res Date: 2015-04-06 Impact factor: 4.466
Authors: Ronald B Easley; Bradley S Marino; Jacky Jennings; Amy E Cassedy; Kathleen K Kibler; Ken M Brady; Dean B Andropoulos; Marissa Brunetti; Charles W Hogue; Eugenie S Heitmiller; Jennifer K Lee; James Spaeth; Allen D Everett Journal: Cardiol Young Date: 2017-08-24 Impact factor: 1.093
Authors: Stephanie L McKenney; Fahad F Mansouri; Allen D Everett; Ernest M Graham; Irina Burd; Priya Sekar Journal: Cardiol Young Date: 2016-01-20 Impact factor: 1.093
Authors: Zhicheng Jin; Zongming Fu; Jun Yang; Juan Troncosco; Allen D Everett; Jennifer E Van Eyk Journal: Proteomics Date: 2013-08-07 Impact factor: 3.984